Pharmaceutical companies Pfizer and BioNTech are actively responding to a lawsuit launched by biotech company Promosome LLC. The lawsuit claims that Pfizer and BioNTech’s COVID-19 vaccine infringes on a patent concerning messenger RNA (mRNA) technology. This technology plays a decisive role in teaching the body’s immune system to detect and combat disease-causing viruses.
In a counter to these charges, Pfizer and BioNTech have argued that Promosome LLC did not provide information on prior art that revealed the purported invention. Prior art, a term used in patent law, refers to any evidence that an invention is already known and could thereby influence the novelty and validity of the patent in question.
As this legal dispute unfolds, legal professionals will be closely following the case for its potential implications on patent laws surrounding vital technologies such as mRNA. The lawsuit raises critical questions about the stakes for vaccine production, the role of prior art in patent disputes and the lag between scientific innovation and legal protection of these advancements.
To read more about this ongoing lawsuit and the contentious debate surrounding the mRNA patent, visit Law360’s full report.